Image

Bladder EpiCheck European Haematuria Study

Bladder EpiCheck European Haematuria Study

Recruiting
45 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed.

Participants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.

Eligibility

Inclusion Criteria:

  1. Participants aged 45 years or older
  2. Participants who are willing and able to provide written informed consent and adhere to study procedures
  3. Participants presenting with visible and/or non-visible haematuria within 6 months prior to study enrollment
  4. Participants scheduled to undergo standard of care cystoscopy for urinary bladder examination within 60 days after study enrollment
  5. Participants who are able to produce at least 10 ml of voided urine

Exclusion Criteria:

  1. Participants with history of urothelial cancer in the bladder and/or upper urinary tract
  2. Participants who had prior cystoscopy for haematuria within the past 2 years
  3. Participants previously enrolled in this study
  4. Participants treated for prostate cancer within the last 12 months
  5. Participants treated for kidney cancer within the last 12 months
  6. Participants with untreated urinary tract infection
  7. Participants with symptomatic urinary tract stones (e.g. flank pain)
  8. Participants on dialysis for end stage renal failure
  9. Participants with a long term urinary catheter
  10. Pregnancy (self-reported)
  11. Participants who, because of medical status, or frailty is not expected to be able to complete the full diagnostic pathway

Study details
    Hematuria
    Cystoscopy
    Urothelial Carcinoma Bladder
    Urothelial Carcinoma of the Renal Pelvis and Ureter
    Urothelial Carcinoma of the Urinary Bladder

NCT06818136

Nucleix Ltd.

1 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.